MedRx Co.,Ltd.

MedRx is a public Japanese pharmaceutical company devoting to creating and developing technologies and products that fulfill the unmet needs of patients and physicians. Through capitalizing on our platform technologies – “Ionic Liquid” and “Microneedle array patch”, MedRx attempts to create novel medicines.

MedRx is well-experienced in developing novel transdermal therapies by capitalizing our proprietary ILS technology, in order to overcome hurdles for conventional transdermal technologies (accomplishing increased solubility and absorbability of APIs / delivery of new therapeutic modalities, etc.). In other word, MedRx is skilled in developing novel treatments by using APIs which are:

• Matching the benefits of transdermal administration route, but rarely passing through the skin under conventional technologies, and / or

• Highly-potential, but failing to fully deliver its intrinsic potentials under oral / other administration routes due to its oral low BA, short durations, and so on.

On the other hand, MedRx has also found that our ILS technology may improve / enhance, not limited to the transdermal / topical absorbability, but also the oral absorbability of some APIs. In other word, MedRx's Ionic Liquid System may allow APIs with weak absorbability to be available as oral formulations by means of increasing their absorbability.

MedRx is unremittingly working on developing / expanding our ILS. In this spirit, MedRx is seeking partnering opportunities in order to develop novel therapies in collaboration with partners and partners’ proprietary APIs.